References:
1. Puri R, Auffret V, Rodés-Cabau J: Bioprosthetic Valve Thrombosis. J Am Coll Cardiol. 2017; 24;69(17):2193–211.
2. Egbe AC, Pislaru SV, Pellikka PA, et al: Bioprosthetic Valve Thrombosis Versus Structural Failure: Clinical and Echocardiographic Predictors. J Am Coll Cardiol . 2015;66(21):2285-2294.
3. Nishimura RA, Otto CM, Bonow RO, et al: 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol . 2017;70(2):252-289.
4. Baumgartner H, Falk V, Bax JJ, et al: 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J . 2017;38(36):2739-2791.
5. Butnaru A, Shaheen J, Tzivoni D, et al: Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol . 2013;112(9):1439-1444.
6. Oliver JM, Gallego P, Gonzalez A, et al: Bioprosthetic mitral valve thrombosis: Clinical profile, transesophageal echocardiographic features, and follow-up after anticoagulant therapy. Journal of the American Society of Echocardiography . 1996;9(5):691-699.
7. Egbe AC, Connolly HM, Pellikka PA, et al: Outcomes of Warfarin Therapy for Bioprosthetic Valve Thrombosis of Surgically Implanted Valves: A Prospective Study. J Am Coll Cardiol Intv . 2017;10(4):379-387.
8. Petrescu I, Egbe AC, Ionescu F, et al: Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis. J Am Coll Cardiol . 2020;75(8):857-866.